Evaluation of binding property to tau protein, systemic pharmacokinetics and effective dose of [11C]PBB3

Evaluation of binding property to tau protein, systemic pharmacokinetics and effective dose of [11C]PBB3 - Proper evaluation of [11C]PBB3 as in vivo tau imaging agent

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008242

Enrollment

Registered

2012-06-30

Start date

2012-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy volunteer and Alzheimer&#39

Interventions

PET/MRI/psychological batteries/neurological examinations PET/MRI/psychological batteries/neurological examinations

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: [healthy volunteer] 50y.o.<=Age<=88y.o., cognitive normal subjects without severe physical complication [Alzheimer's disease (AD)] 50y.o.<=Age<=88y.o., based on J-ADNI core study [Comprehensive Research on Aging and Health, The Ministry of Health Labour and Welfare, (19122701)] except CDR and MMSE, 0.5<=CDR<=2, 12<=MMSE<=26

Exclusion criteria

Exclusion criteria: 1.psychiatric complications such as drug abuse 2.other organic brain complications such as symptomatic stroke, PD-related disorders and other neurodegenrative diseases 3.severe physical complications 4.subject who has metal such as pacemaker in the body, and cannot perform MRI examination 5.subjects with tattoo 6.subject with claustrophobia who cannot perform MRI examination 7.exclude the patients who are recognized as inadequate patients by doctors with resposibility in this study

Design outcomes

Primary

Measure	Time frame
Quantitative measurement of binding property to tau protein, systemic pharmacokinetics and effective dose in PET	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026